121.65 USD
-0.27 (-0.22%)
121.65 USD
0 (0%)
TMDX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. TMDX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. TMDX is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make TMDX suitable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year TMDX was profitable.
In the past year TMDX had a positive cash flow from operations.
TMDX had negative earnings in 4 of the past 5 years.
In the past 5 years TMDX reported 4 times negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 9.70%, TMDX belongs to the best of the industry, outperforming 93.55% of the companies in the same industry.
With an excellent Return On Equity value of 25.84%, TMDX belongs to the best of the industry, outperforming 96.77% of the companies in the same industry.
TMDX has a better Return On Invested Capital (8.75%) than 88.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROIC | 8.75% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of TMDX (16.20%) is better than 93.01% of its industry peers.
TMDX has a better Operating Margin (16.94%) than 87.63% of its industry peers.
With a decent Gross Margin value of 60.28%, TMDX is doing good in the industry, outperforming 61.29% of the companies in the same industry.
In the last couple of years the Gross Margin of TMDX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TMDX is still creating some value.
Compared to 1 year ago, TMDX has more shares outstanding
The number of shares outstanding for TMDX has been increased compared to 5 years ago.
The debt/assets ratio for TMDX has been reduced compared to a year ago.
2.2 Solvency
TMDX has an Altman-Z score of 5.26. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.26, TMDX belongs to the top of the industry, outperforming 80.11% of the companies in the same industry.
The Debt to FCF ratio of TMDX is 4.24, which is a neutral value as it means it would take TMDX, 4.24 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.24, TMDX belongs to the top of the industry, outperforming 80.11% of the companies in the same industry.
TMDX has a Debt/Equity ratio of 1.43. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.43, TMDX is doing worse than 77.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Altman-Z | 5.26 |
ROIC/WACC1.09
WACC8.02%
2.3 Liquidity
TMDX has a Current Ratio of 7.69. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TMDX (7.69) is better than 88.71% of its industry peers.
TMDX has a Quick Ratio of 7.13. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 7.13, TMDX belongs to the best of the industry, outperforming 89.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 162.77% over the past year.
TMDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.20%.
TMDX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 79.64% yearly.
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
The Earnings Per Share is expected to grow by 44.52% on average over the next years. This is a very strong growth
TMDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.23% yearly.
EPS Next Y163.67%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y44.52%
Revenue Next Year39.67%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 49.25 indicates a quite expensive valuation of TMDX.
68.82% of the companies in the same industry are more expensive than TMDX, based on the Price/Earnings ratio.
TMDX is valuated expensively when we compare the Price/Earnings ratio to 26.51, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 41.17, the valuation of TMDX can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 70.43% of the companies listed in the same industry.
TMDX is valuated expensively when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.25 | ||
| Fwd PE | 41.17 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 69.89% of the companies listed in the same industry.
77.42% of the companies in the same industry are more expensive than TMDX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.47 | ||
| EV/EBITDA | 34.54 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
TMDX's earnings are expected to grow with 53.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.3
PEG (5Y)N/A
EPS Next 2Y71.04%
EPS Next 3Y53.35%
5. Dividend
5.1 Amount
No dividends for TMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
121.65
-0.27 (-0.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.26%
Inst Owner Change1.46%
Ins Owners2.95%
Ins Owner Change-0.16%
Market Cap4.16B
Revenue(TTM)566.35M
Net Income(TTM)91.77M
Analysts83
Price Target148.84 (22.35%)
Short Float %21.09%
Short Ratio7.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)1.74%
PT rev (3m)-0.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.51%
EPS NY rev (1m)0.62%
EPS NY rev (3m)10.25%
Revenue NQ rev (1m)-0.12%
Revenue NQ rev (3m)0.3%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 49.25 | ||
| Fwd PE | 41.17 | ||
| P/S | 7.34 | ||
| P/FCF | 34.47 | ||
| P/OCF | 23.31 | ||
| P/B | 11.7 | ||
| P/tB | 12.17 | ||
| EV/EBITDA | 34.54 |
EPS(TTM)2.47
EY2.03%
EPS(NY)2.95
Fwd EY2.43%
FCF(TTM)3.53
FCFY2.9%
OCF(TTM)5.22
OCFY4.29%
SpS16.57
BVpS10.4
TBVpS10
PEG (NY)0.3
PEG (5Y)N/A
Graham Number24.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.84% | ||
| ROCE | 11.08% | ||
| ROIC | 8.75% | ||
| ROICexc | 18.94% | ||
| ROICexgc | 19.61% | ||
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% | ||
| FCFM | 21.29% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Debt/EBITDA | 4.16 | ||
| Cap/Depr | 224.51% | ||
| Cap/Sales | 10.19% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.57% | ||
| Profit Quality | 131.41% | ||
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 | ||
| Altman-Z | 5.26 |
F-Score7
WACC8.02%
ROIC/WACC1.09
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y163.67%
EPS Next 2Y71.04%
EPS Next 3Y53.35%
EPS Next 5Y44.52%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.67%
Revenue Next 2Y29.73%
Revenue Next 3Y25.56%
Revenue Next 5Y21.23%
EBIT growth 1Y205.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year317.92%
EBIT Next 3Y87.46%
EBIT Next 5Y68.49%
FCF growth 1Y187.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y802.91%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
Can you provide the valuation status for TRANSMEDICS GROUP INC?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
How financially healthy is TRANSMEDICS GROUP INC?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 7 / 10.